EP3694590A1 — Drug delivery systems and related methods
Assigned to Pearl Therapeutics Inc · Expires 2020-08-19 · 6y expired
What this patent protects
Systems and methods for isolating and / or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce the amount of water vapor within the drug delivery tract -this. For example, the invention relates to a metered dose inhaler for delivering an aerosol …
USPTO Abstract
Systems and methods for isolating and / or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce the amount of water vapor within the drug delivery tract -this. For example, the invention relates to a metered dose inhaler for delivering an aerosol drug or other material to a user. The aerosol medication or other material may be evacuated from a discharge passage within the inhaler to an inhalation passageway for inhalation by a user, and the inhaler may include a sealing designed to selectively isolate the exhaust passage from the inhalation passage and the external environment during inactivity. The inhaler may further include a desiccant material disposed to remove moisture from the isolated discharge passage. In other cases, a desiccant material may be arranged to remove moisture from the inhaler vent passage without isolating the discharge passage during inactivity.
Drugs covered by this patent
- Pulmicort Respules (BUDESONIDE) · AstraZeneca K.K.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.